Comparing aTyr Pharma (NASDAQ:LIFE) & Aptose Biosciences (NASDAQ:APTO)

Share on StockTwits

aTyr Pharma (NASDAQ:LIFE) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Earnings and Valuation

This table compares aTyr Pharma and Aptose Biosciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
aTyr Pharma N/A N/A -$34.51 million ($16.11) -0.30
Aptose Biosciences N/A N/A -$28.87 million ($0.86) -3.22

Aptose Biosciences is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for aTyr Pharma and Aptose Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
aTyr Pharma 0 3 1 0 2.25
Aptose Biosciences 0 0 6 0 3.00

aTyr Pharma currently has a consensus target price of $16.57, suggesting a potential upside of 237.41%. Aptose Biosciences has a consensus target price of $6.40, suggesting a potential upside of 131.05%. Given aTyr Pharma’s higher probable upside, research analysts plainly believe aTyr Pharma is more favorable than Aptose Biosciences.

Profitability

This table compares aTyr Pharma and Aptose Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
aTyr Pharma N/A -81.33% -51.98%
Aptose Biosciences N/A -182.77% -152.74%

Insider & Institutional Ownership

30.4% of aTyr Pharma shares are owned by institutional investors. Comparatively, 6.2% of Aptose Biosciences shares are owned by institutional investors. 27.7% of aTyr Pharma shares are owned by insiders. Comparatively, 7.3% of Aptose Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

aTyr Pharma has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Summary

aTyr Pharma beats Aptose Biosciences on 7 of the 11 factors compared between the two stocks.

About aTyr Pharma

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD. The company has a collaboration with the University of Nebraska Medical Center for the development of neuropilin-2 receptor biology; and a research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases. The company was founded in 2005 and is headquartered in San Diego, California.

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply